Data as of Jan 30
| -0.69 / -2.01%|
The 6 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 34.50, with a high estimate of 39.00 and a low estimate of 22.00. The median estimate represents a +2.50% increase from the last price of 33.66.
The current consensus among 7 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.